PFE - Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps While Pfizer Trades Lower | Benzinga
Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide with 391 subjects.
Friday, Pfizer Inc (NYSE: PFE) reported topline data from the Phase 2b trial of danuglipron. Shares fell as the patients in the study discontinued at rates greater than 50% across all doses compared to 40% of patients on placebo.
At Week 48, subjects receiving pemvidutide achieved mean weight losses of 10.3%, 11.2%, 15.6%, and 2.2% at the 1.2 mg, 1.8 ...